04.21.08 - Gene Express, Inc. announced that it has signed an agreement with the Division of Patents & Licensing Research Office at the University of South Florida (USF) to license some of their gene expression technology necessary to develop prognostic tests for cisplatin and irinotecan chemoresistance.
The ability to assess patients for resistance to chemotherapeutics prior to chemotherapy would offer physicians an important tool in providing appropriate chemotherapy to patients afflicted with cancers of the lung and colon. Mechanisms of chemoresistance likely involve multiple gene products involved in DNA repair, drug uptake and other unspecified processes... Gene Express' Press Release -
